NIKKEI 225
27,424.34 -262.06 (-0.95%) HANG SENG
19,157.00 +342.18 (+1.82%) CRUDE OIL
72.56 +0.55 (+0.76%) GOLD FUTURES
1,793.80 -4.20 (-0.23%) DOW
33,597.92 +1.58 (+0.00%) BTC-GBP
13,800.49 -257.37 (-1.83%)
Pfizer Inc. (PFE)
After hours:
| Previous close | 49.71 |
| Open | 49.75 |
| Bid | 50.10 x 1000 |
| Ask | 50.53 x 1800 |
| Day's range | 49.75 - 51.15 |
| 52-week range | 41.45 - 61.71 |
| Volume | |
| Avg. volume | 20,217,530 |
| Market cap | 282.013B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 9.62 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.60 (3.22%) |
| Ex-dividend date | 03 Nov 2022 |
| 1y target est | N/A |
- Business Wire
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
NEW YORK, December 07, 2022--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, as submitted for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
- Business Wire
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease
NEW YORK & CAMBRIDGE, Mass., December 06, 2022--Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. PLpro is an essential enzyme, which, along with the main protease (Mpro), plays an important role in viral replication. This program will expand Pfizer’s innovative anti-infective p
- Business Wire
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day
NEW YORK, December 01, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Near-Term Launches + High-Value Pipeline Day on Monday, December 12, 2022 from 1:00 p.m. EST to 6:00 p.m. EST, with an approximately 30 minute break at the midpoint. Pfizer business executives and scientific leadership will provide updates on the company’s potential near-term product launches and key high-value pipeline programs, both of which are expected to be pri
